AXSM Stock Overview
A biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AXSM from our risk checks.
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$92.69 |
| 52 Week High | US$98.40 |
| 52 Week Low | US$55.02 |
| Beta | 1.25 |
| 11 Month Change | 11.55% |
| 3 Month Change | 29.55% |
| 1 Year Change | 12.75% |
| 33 Year Change | 254.18% |
| 5 Year Change | 228.57% |
| Change since IPO | 960.53% |
Recent News & Updates
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Recent updates
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Shareholder Returns
| AXSM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.4% | -2.7% | -3.4% |
| 1Y | 12.7% | 15.8% | 19.6% |
Return vs Industry: AXSM underperformed the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: AXSM underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| AXSM volatility | |
|---|---|
| AXSM Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AXSM has not had significant price volatility in the past 3 months.
Volatility Over Time: AXSM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 589 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| AXSM fundamental statistics | |
|---|---|
| Market cap | US$4.52b |
| Earnings (TTM) | -US$308.55m |
| Revenue (TTM) | US$291.49m |
15.3x
P/S Ratio-14.4x
P/E RatioIs AXSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXSM income statement (TTM) | |
|---|---|
| Revenue | US$291.49m |
| Cost of Revenue | US$28.26m |
| Gross Profit | US$263.23m |
| Other Expenses | US$571.78m |
| Earnings | -US$308.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.43 |
| Gross Margin | 90.30% |
| Net Profit Margin | -105.85% |
| Debt/Equity Ratio | 174.4% |
How did AXSM perform over the long term?
See historical performance and comparison